Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)-Reference-Cited by-同舟云学术

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

Published:2024-05 Issue: Volume: Page:
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Hanauer Stephen B.,Sands Bruce E.,Schreiber Stefan,Danese Silvio,Kłopocka Maria,Kierkuś Jarosław,Kulynych Roman,Gonciarz Maciej,Sołtysiak Artur,Smoliński Patryk,Srećković Slobodan,Valuyskikh Ekaterina,Lahat Adi,Horyński Marek,Gasbarrini Antonio,Osipenko Marina,Borzan Vladimir,Kowalski Maciej,Saenko Daria,Sardinov Ruslan,Lee Sang Joon,Kim Sunghyun,Bae Yunju,Lee Sunhee,Lee Seulgi,Lee Joon Ho,Yang Siyoung,Lee Jimin,Lee Juhyun,Kim Jong Min,Park Gahee,Sandborn William J.,Colombel Jean-Frederic^ORCID

Funder

Celltrion Inc

Publisher

Elsevier BV

Reference37 articles.

1. Unravelling the pathogenesis of inflammatory bowel disease;Xavier;Nature,2007

2. The influence of cytokines on the complex pathology of ulcerative colitis;Nakase;Autoimmun Rev,2022

3. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues;Peyrin-Biroulet;Therap Adv Gastroenterol,2021

4. Infliximab for induction and maintenance therapy for ulcerative colitis;Rutgeerts;N Engl J Med,2005

5. Remicade® (infliximab): 20 years of contributions to science and medicine;Melsheimer;Biologics,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shot Heard Around the world? Subcutaneous Infliximab as Maintenance Therapy for Inflammatory Bowel Disease;Gastroenterology;2024-07